Johnson & Johnson, Novo and Alphabet all invested in the clinical data platform developer’s latest round, as big data analytics moves further into healthcare.

Pharmaceutical firms Johnson & Johnson and Novo have co-led a $150m series E round for US-based clinical data platform developer Verana Health, highlighting the growing importance of data analytics in the healthcare market.

GV, a subsidiary of internet and technology group Alphabet, also took part in the round, as did pharmaceutical firm Merck & Co’s Global Health Innovation Fund, Casdin Capital, THVC, Breyer Capital and private investor Brook Byers.

Johnson & Johnson and Novo took part through subsidiaries Johnson &…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn